RadioMedix, Inc.
PrivateLast Round
Series A
Oct 7, 2022
Total Funding Raised
$44M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
RadioMedix, Inc. is a biotechnology company that develops and commercializes targeted radiopharmaceuticals for the diagnosis, monitoring, and therapy of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Imaging, Precision Medicine, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
RadioMedix, Inc. Comparables
Compare RadioMedix, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ratio Therapeutics Inc. | 77% | |
| AdvanCell | 76% | |
| Aktis Oncology | 76% |
RadioMedix, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 7, 2022 | ||||
| Grant | Nov 18, 2021 | ||||
| Grant | Jan 22, 2019 |
RadioMedix, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| NIH RADx | Grant |
| Portland Investment Counsel Inc. | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors grew 102% MoM, reaching 2.6K.
- Jul 17, 2026
Open roles increased to 14, 3.5x the trailing average.
Recent news
Latest coverage and updates
- hiresJul 15, 2026
RadioMedix Inc. hired Brian A. Markison as board of directors on Jul 1st '26.
RadioMedix, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access